OpGen

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.

The Nasdaq has told the firm that it is in compliance with all applicable listing standards and that its meeting with a hearings panel has been cancelled.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.

The company is taking the step to continue listing its shares on the Nasdaq, which had warned OpGen that did not meet a listing requirement calling for a minimum bid price of $1 per share. 

OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.

OpGen expects to begin clinical validation studies for the AMR Gene Panel u5.47 for complicated urinary tract infections in Q4.

The company said it achieved important milestones in the development of its first Acuitas Rapid Test and the Acuitas Lighthouse Knowledgebase during the quarter.

The Gaithersburg, Maryland-based firm intends to use the proceeds for general corporate purposes, including working capital and product development.

The firm said it will offer 25 million units consisting of common stock and common warrants at $.40 per unit. 

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.